New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

S Arbuck, L Shankar - European journal of cancer, 2009 - Elsevier
BACKGROUND: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …
被引用次数：28180 相关文章
[PDF] researchgate.net

[PDF][PDF] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA Eisenhauera, P Therasseb… - EUROPEAN …, 2009 - researchgate.net
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …
[PDF] eortc.org

[PDF][PDF] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA Eisenhauera, P Therasseb, J Bogaertsc… - EUROPEAN …, 2009 - project.eortc.org
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …
[PDF] academia.edu

[PDF][PDF] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA Eisenhauera, P Therasseb, J Bogaertsc… - EUROPEAN …, 2009 - academia.edu
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …

[引用][C] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA EISENHAUER, P THERASSE… - European journal of …, 2009 - pascal-francis.inist.fr
New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1.1)
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
[PDF] psu.edu

[PDF][PDF] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA Eisenhauera, P Therasseb, J Bogaertsc… - … JOURNAL OF CANCER, 2009 - Citeseer
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E Eisenhauer, P Therasse, J Bogaerts… - European Journal of …, 2009 - repub.eur.nl
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …
[PDF] recist.com.br

[PDF][PDF] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA Eisenhauera, P Therasseb, J Bogaertsc… - EUROPEAN …, 2009 - recist.com.br
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …
[PDF] fantasticbioimaging.com

[PDF][PDF] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA Eisenhauera, P Therasseb… - EUROPEAN …, 2009 - fantasticbioimaging.com
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

EA Eisenhauer, P Therasse… - … Journal of Cancer, 2009 - mayoclinic.elsevierpure.com
Background: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …